During the past decade, Capital Allergy & Respiratory Disease Center conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 3 clinical trials were completed, i.e. on average, 150% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Capital Allergy & Respiratory Disease Center" #1 sponsor was "Hoffmann-La Roche" with 2 trials, followed by "Baxalta now part of Shire" with 1 trials sponsored, "Genentech, Inc." with 1 trials sponsored, "Gilead Sciences" with 1 trials sponsored and "Meda Pharmaceuticals" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

According to Clinical.Site data, the most researched conditions in "Capital Allergy & Respiratory Disease Center" are "Cystic Fibrosis" (3 trials), "Asthma" (2 trials), "Atopic Dermatitis" (1 trials), "COPD" (1 trials) and "Perennial Allergic Rhinitis" (1 trials). Many other conditions were trialed in "Capital Allergy & Respiratory Disease Center" in a lesser frequency.

Most popular intervention types in "Capital Allergy & Respiratory Disease Center" are "Drug" (9 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "AZLI 75 mg three times a day (TID)" (1 trials), "Azelastine hydrochloride nasal spray 0.10%" (1 trials), "Azelastine hydrochloride nasal spray 0.15%" (1 trials) and "Ciclesonide nasal aerosol 37 mcg" (1 trials). Other intervention names were less common.

The vast majority of trials in "Capital Allergy & Respiratory Disease Center" are 10 trials for "All" genders.

Currently, there are NaN active trials in "Capital Allergy & Respiratory Disease Center". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Capital Allergy & Respiratory Disease Center, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Capital Allergy & Respiratory Disease Center, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 0 trials that are defined as “Not Applicable".